Rosacea

Rosacea is a chronic inflammatory dermatological condition characterized by persistent centrofacial erythema (redness concentrated in the central area of the face). The disorder primarily manifests as facial redness, papules (small raised bumps), pustules (pus-filled lesions), and telangiectasia (visible small blood vessels), predominantly affecting the cheeks, nose, chin, and forehead. Unlike acne vulgaris, rosacea does not present with comedones (blackheads or whiteheads) and typically develops in adulthood.

Rosacea affects approximately 1 in 20 individuals (5.46% global prevalence), making it a relatively common dermatological condition. The disorder demonstrates specific demographic patterns:

• Age demographics: Peak onset occurs between 30-50 years of age
• Gender distribution: Equal prevalence in males and females, though phymatous changes (skin thickening) occur more frequently in men
• Ethnic predisposition: Higher prevalence in individuals of Northern European descent, particularly those with fair skin phototypes
• Genetic factors: Familial clustering observed in approximately 30% of cases, suggesting hereditary predisposition

Rosacea presents with variable clinical features that can be categorized into objective signs and subjective symptoms:

Signs (objective, observable findings):

• Persistent centrofacial erythema (facial redness that does not resolve)
• Inflammatory papulopustular lesions (red bumps with or without pus, distinct from acne)
• Telangiectasia (dilated superficial blood vessels creating visible red lines)
• Flushing episodes (transient redness triggered by specific stimuli)
• Facial edema (swelling, particularly around the eyes and cheeks)
• Phymatous changes (skin thickening and enlargement, most commonly affecting the nose)
• Ocular signs (conjunctival redness, lid margin inflammation, visible blood vessels in eyes)

Symptoms (subjective, patient-reported experiences):

• Burning sensations (feeling of heat or warmth in affected areas)
• Stinging sensations (sharp, prickling discomfort)
• Facial tenderness (sensitivity to touch in affected areas)
• Ocular symptoms (eye dryness, grittiness, irritation, foreign body sensation)
• Pruritus (itching, though less common than burning/stinging)

Disease progression:

Rosacea typically follows a chronic relapsing-remitting course with periods of exacerbation alternating with relative quiescence.

The etiology of rosacea involves multiple interconnected pathogenic mechanisms:

• Primary pathogenic mechanisms: Dysregulation of the innate immune system, neurovascular dysfunction, and altered cutaneous microbiome composition
• Contributing factors: Genetic predisposition, chronic ultraviolet exposure, and environmental influences
• Triggering elements: Heat exposure, spicy foods, alcoholic beverages (particularly red wine), emotional stress, physical exertion, and certain cosmetic products
• Microbial factors: Increased density of Demodex folliculorum mites and potential bacterial involvement, though rosacea is not considered contagious

Diagnosis of rosacea is primarily clinical, based on characteristic morphological features:

• Clinical assessment methods: Visual examination focusing on the distribution and morphology of lesions, assessment of triggering factors, and evaluation for ocular involvement
• Diagnostic criteria: Based on the 2017 National Rosacea Society consensus, requiring either persistent centrofacial erythema or phymatous changes for diagnosis
• Differential considerations: Distinction from acne vulgaris (absence of comedones), seborrheic dermatitis (different distribution pattern), systemic lupus erythematosus (serological differences), and photodermatitis (exposure patterns)

Therapeutic management of rosacea employs a multimodal approach:

• First-line therapeutic approaches:

  • Topical anti-inflammatory agents (metronidazole, ivermectin, azelaic acid)
  • Topical vasoconstrictors for persistent erythema (brimonidine, oxymetazoline)
  • Systemic tetracyclines for moderate to severe papulopustular disease

• Alternative treatment modalities:

  • Laser and light-based therapies for vascular components
  • Low-dose isotretinoin for refractory cases
  • Surgical intervention for advanced phymatous changes

• Lifestyle modifications and self-care:

  • Identification and avoidance of personal triggering factors
  • Daily broad-spectrum photoprotection (minimum SPF 30)
  • Gentle skincare regimen with pH-balanced cleansers

• Rosacea is a chronic condition requiring long-term management rather than cure
• Early intervention can prevent disease progression and minimize cosmetic impact
• Treatment typically involves combination therapy tailored to individual phenotype
• Maintenance therapy is usually necessary to prevent relapse
• Professional consultation is recommended for persistent facial erythema or inflammatory lesions
• Ocular symptoms warrant ophthalmological evaluation to prevent complications

• Incidence: 1.65 per 1,000 person-years in Caucasian populations
• Prevalence:
  • Global: 5.46% (95% CI: 4.91-6.02%)
  • US: 5.3% of adults
  • Northern Europe: Up to 10%
  • Asia: 2-3%
• Demographics:
  • Peak onset: 30-50 years (mean age 43.5 years)
  • Gender ratio: 1:1 (phymatous subtype M:F = 5:1)
  • Fitzpatrick skin types I-III: 95% of cases
• Geographic distribution:
  • Highest: Northern European countries (Ireland 13.9%, Germany 12.3%)
  • Moderate: North America, Western Europe
  • Lowest: Africa, Asia
• Trends:
  • Increasing recognition of rosacea in skin of color
  • Earlier diagnosis due to improved awareness
  • Rising incidence attributed to environmental factors

Etiology

• Genetic predisposition (heritability ~46%)
  • HLA-DRB1*03:01 association (OR 2.3)
  • VEGF polymorphisms
  • GST gene variants affecting detoxification
• Environmental factors
  • UV radiation (OR 1.8 for high exposure)
  • Temperature extremes
  • Dietary factors (capsaicin, cinnamaldehyde)
• Risk factor analysis
  • Family history: OR 3.8 (95% CI: 2.9-4.8)
  • Fair skin phototype: OR 2.4
  • Chronic sun damage: OR 1.7

Pathophysiology

• Innate immune activation

  • TLR-2 upregulation → kallikrein 5 (KLK5) activation
  • Cathelicidin (LL-37) processing → pro-inflammatory peptides
  • NLRP3 inflammasome activation → IL-1β release
  • Matrix metalloproteinase (MMP) overexpression

• Adaptive immune response

  • Th1/Th17 polarization (IL-17A, IFN-γ elevation)
  • CD4+ T-cell infiltration
  • B-cell involvement with autoantibody production

• Neurovascular dysregulation

  • TRPV1, TRPV2, TRPV4 channel dysfunction
  • CGRP, substance P, VIP release
  • Endothelial dysfunction with NO dysregulation
  • Angiogenesis and lymphangiogenesis (VEGF-A, VEGF-C)

• Microbiome dysbiosis

  • Demodex folliculorum density: >5/cm² (normal <1/cm²)
  • Bacillus oleronius within Demodex → TLR activation
  • Reduced microbial diversity
  • Staphylococcus epidermidis increase

Primary features

• Persistent centrofacial erythema (100% diagnostic phenotype)
  • Spares periocular and perioral areas
  • Violaceous hue in skin of color
  • Duration >3 months
• Inflammatory papulopustules (43.2% of cases)
  • Monomorphic appearance
  • Absence of comedones (key differentiator from acne)
  • Central facial distribution
• Telangiectasia (63% of ETR subtype)
  • Linear branching vessels 0.2-1.0mm diameter
  • Nasal alae, medial cheeks predominance
• Phymatous changes (7.4% overall, 15% of men >40 years)
  • Rhinophyma (95% of phymatous)
  • Gnathophyma, metophyma, otophyma, blepharophyma (rare)

Secondary features

• Neurosensory symptoms (71% of patients)
  • Burning (36%)
  • Stinging (28%)
  • Pruritus (19%)
• Facial edema (18% of cases)
  • Solid, non-pitting
  • Worse in morning
• Xerosis (rough, scaly texture in 24%)

Variants and subtypes

• Granulomatous rosacea (lupoid/tuberculoid variant)
  • Yellow-brown papules
  • Diascopy: apple-jelly nodules
  • Histology: epithelioid granulomas
• Rosacea fulminans (pyoderma faciale)
  • Acute onset <3 weeks
  • Confluent nodules, sinus tracts
  • Systemic symptoms possible
• Pediatric rosacea
  • Mean age 5.7 years
  • Predominant flushing, less papulopustular

Complications

• Ocular (50-70% prevalence)
  • Anterior blepharitis (57%)
  • Meibomian gland dysfunction (35%)
  • Conjunctival hyperemia (31%)
  • Corneal complications (5-10%): SPK, infiltrates, ulceration
  • Vision loss (<1% but serious)
• Psychosocial
  • Depression (OR 2.76)
  • Anxiety disorders (OR 2.24)
  • Social phobia (18% prevalence)

Diagnostic criteria

2017 National Rosacea Society Global ROSacea COnsensus (ROSCO) criteria:

• Diagnostic phenotypes (either sufficient for diagnosis):

  1. Persistent centrofacial erythema with periodic intensification
  2. Phymatous changes

• Major phenotypes (≥2 = diagnostic):

  1. Flushing/transient erythema
  2. Inflammatory papules/pustules
  3. Telangiectasia
  4. Ocular manifestations:
     • Lid margin telangiectasia
     • Interpalpebral conjunctival injection
     • Spade-shaped infiltrates
     • Scleritis/sclerokeratitis

Clinical diagnosis

• History taking pearls:

  • Duration and progression of symptoms
  • Trigger identification questionnaire
  • Family history (30% positive)
  • Medication history (topical steroids exacerbate)
  • Quality of life assessment (DLQI, RosaQoL)

• Physical examination techniques:

  • Diascopy to differentiate erythema from telangiectasia
  • Stretch test for background erythema
  • Pinch test for dermal thickening
  • Schirmer test for ocular involvement

• Clinical scoring systems:

  • Investigator Global Assessment (IGA): 0-4 scale
  • Clinician Erythema Assessment (CEA): 0-4 scale
  • National Rosacea Society grading: mild/moderate/severe

Laboratory investigations

• Initial tests (when indicated):

  • ANA, anti-Ro/La (exclude lupus)
  • H. pylori testing (controversial, prevalence 48% vs 36% controls)
  • Demodex density (>5/cm² significant)

• Confirmatory tests:

  • Skin biopsy (atypical presentations only):
    • Perifollicular and perivascular lymphohistiocytic infiltrate
    • Solar elastosis
    • Telangiectasia, sebaceous hyperplasia
    • Demodex in follicles (65% of biopsies)

• Biomarkers (research setting):

  • LL-37 levels (elevated)
  • MMP-2, MMP-9 (increased)
  • VEGF (elevated in ETR)

Imaging

• Dermoscopy findings:

  • Polygonal vessels (87% sensitivity)
  • Linear vessels on erythematous background
  • Follicular plugs with whitish halo
  • Orange-yellowish areas (sebaceous hyperplasia)

• Reflectance confocal microscopy:

  • Dilated blood vessels
  • Inflammatory infiltrate
  • Demodex mites in follicles

• Optical coherence tomography:

  • Increased dermal vascularity
  • Epidermal thickening in phymatous

• Classic findings:

  • Superficial and mid-dermal perivascular infiltrate
  • Lymphocytes, histiocytes, occasional plasma cells
  • Dilated capillaries and venules
  • Solar elastosis (chronic cases)

• Special stains:

  • Periodic acid-Schiff (PAS): Demodex
  • Elastic stains: solar elastosis

• Acne vulgaris:

  • Comedones present (absent in rosacea)
  • Younger age group
  • Truncal involvement

• Seborrheic dermatitis:

  • Greasy yellow scales
  • Nasolabial fold involvement
  • Scalp involvement common

• Lupus erythematosus:

  • Malar rash spares nasolabial folds
  • Photosensitivity more pronounced
  • Positive serology (ANA, anti-dsDNA)
  • Systemic symptoms

• Photodermatitis:

  • Sharp UV-exposed cutoff
  • Spares photoprotected areas
  • History of photosensitizing agent

• Perioral dermatitis:

  • Perioral distribution
  • Spares vermillion border
  • Often related to topical steroids

• Carcinoid syndrome:

  • Episodic whole-body flushing
  • Diarrhea, wheezing
  • Elevated 24-hour urine 5-HIAA

Pharmacological treatment

First-line agents

Topical anti-inflammatory agents:

• Ivermectin 1% cream: Once daily

  • Mechanism: Anti-inflammatory, anti-Demodex
  • Efficacy: 76% achieve IGA 0/1 at 12 weeks
  • NNT: 3.9 (superior to metronidazole)
  • Adults: Apply pea-sized amount daily
  • Duration: 12-16 weeks initial, then maintenance

• Metronidazole: 0.75% gel/cream BID or 1% gel daily

  • Mechanism: Anti-inflammatory (not antimicrobial at these doses)
  • Efficacy: 48% achieve clear/almost clear at 12 weeks
  • NNT: 6.2
  • Pregnancy category B

• Azelaic acid: 15% gel BID or 20% cream BID

  • Mechanism: Anti-inflammatory, antimicrobial, anti-keratinizing
  • Efficacy: 56-70% improvement
  • Safe in pregnancy/lactation
  • May cause initial irritation (20% of patients)

Topical vasoconstrictors (for persistent erythema):

• Brimonidine 0.33% gel: Once daily

  • Mechanism: α2-adrenergic agonist
  • Onset: 30 minutes, peak 3-6 hours
  • Efficacy: 70% achieve ≥1-grade CEA improvement
  • Rebound erythema: 10-20% of patients

• Oxymetazoline 1% cream: Once daily

  • Mechanism: α1A-adrenergic agonist
  • Efficacy: 52% achieve 2-grade CEA reduction
  • Lower rebound risk than brimonidine

Second-line agents

Systemic tetracyclines:

• Doxycycline:

  • Anti-inflammatory dose: 40mg modified-release daily
  • Traditional dose: 50-100mg daily
  • Pediatric: 2mg/kg/day (max 100mg)
  • Renal adjustment: Not needed for CrCl >10
  • Duration: 8-12 weeks, then reassess
  • Photosensitivity precautions required

• Minocycline: 50-100mg BID

  • Extended-release: 45-90mg daily
  • Advantages: Less photosensitivity
  • Monitor: LFTs, CBC (rare lupus-like syndrome)

Systemic retinoids (severe/refractory):

• Isotretinoin:
  • Low-dose: 10mg daily or alternate days
  • Traditional: 0.25-0.3mg/kg/day
  • Duration: 4-6 months
  • Response rate: 90% for phymatous
  • iPLEDGE requirements apply
  • Monitor: LFTs, lipids, CBC

Emerging therapies

• Topical minocycline foam 4%: FDA-approved 2020

  • Once daily application
  • 52% achieve IGA success at 12 weeks

• Encapsulated benzoyl peroxide 5% cream: FDA-approved 2022

  • Microencapsulation reduces irritation
  • Once daily application

• Oral β-blockers:

  • Carvedilol 6.25mg BID
  • Propranolol 20-40mg TID
  • For flushing/erythema

Non-pharmacological interventions

Laser and energy-based devices:

• Pulsed dye laser (PDL): 585-595nm

  • Settings: 7-10 J/cm², 6-10mm spot, 10-40ms pulse
  • Sessions: 3-5 treatments, 4-week intervals
  • Efficacy: 75% reduction in erythema

• Intense pulsed light (IPL): 515-1200nm

  • Customized filters for vascular targets
  • Efficacy: 77% patient satisfaction
  • Also improves skin texture

• Nd:YAG laser: 1064nm

  • For resistant/deeper vessels
  • Settings: 120-150 J/cm²

Surgical interventions (phymatous rosacea):

• CO2 laser ablation
• Electrosurgery
• Dermabrasion
• Surgical debulking

Treatment algorithms

Mild rosacea (IGA 2):

1. Topical metronidazole or azelaic acid
2. Add brimonidine for erythema if needed
3. Maintenance with topical agent

Moderate rosacea (IGA 3):

1. Topical ivermectin + oral doxycycline 40mg
2. Continue topical after oral discontinued (8-12 weeks)
3. Add laser therapy for telangiectasia

Severe rosacea (IGA 4):

1. Oral doxycycline/minocycline + topical ivermectin
2. Consider isotretinoin if inadequate response
3. Laser/surgical intervention for phymatous changes

Monitoring

• Clinical assessment at 4, 8, 12 weeks
• IGA and CEA scoring
• Quality of life measures (DLQI, RosaQoL)
• Adverse effect monitoring
• Maintenance therapy adjustment

Pediatric considerations

• Prevalence: 0.3-2% of pediatric dermatology patients
• Mean age onset: 5.7 years (range 2-14)
• Clinical features: Predominantly flushing, less papulopustular
• Treatment:
  • Topical metronidazole 0.75% (first-line)
  • Oral erythromycin 20-40mg/kg/day divided BID
  • Avoid tetracyclines <8 years
• Prognosis: Often improves with puberty

Pregnancy and lactation

• Exacerbation in 30% during pregnancy
• Safe treatments:
  • Azelaic acid (Category B)
  • Metronidazole topical (Category B)
  • Erythromycin oral (Category B)
• Avoid:
  • Tetracyclines (Category D)
  • Isotretinoin (Category X)
  • Brimonidine (Category B, but limited data)

Geriatric considerations

• Later onset variant (>60 years) in 15%
• More severe phymatous changes
• Drug interactions with polypharmacy
• Dose adjustments for renal function
• Increased photosensitivity with tetracyclines

Immunocompromised patients

• HIV: Increased severity, papulopustular predominance
• Transplant recipients: Tacrolimus-induced rosacea-like dermatitis
• Modified approach: Lower threshold for systemic therapy

• Natural history:

  • Untreated: Progressive worsening in 48% over 10 years
  • Spontaneous improvement: <10%
  • Fluctuating course with flares and remissions

• With treatment:

  • Topical therapy response: 40-80% achieve IGA 0/1
  • Systemic therapy response: 70-90% significant improvement
  • Maintenance required in 80% to prevent relapse
  • Mean time to relapse without maintenance: 3-6 months

• Prognostic factors:

  • Favorable: Early treatment, mild disease, good compliance
  • Unfavorable: Phymatous changes, ocular involvement, poor trigger control

• Quality of life impact:

  • DLQI scores: Mean 8.2 (moderate-severe impact)
  • Work productivity loss: 18% reported
  • Social avoidance: 41% of patients

• Mortality: No increased mortality risk

Primary prevention

• Sun protection: Daily SPF 30+ broad-spectrum, physical blockers preferred
• Trigger diary and avoidance strategies
• Gentle skincare: pH 5.5-7.0 cleansers, fragrance-free
• Temperature regulation techniques

Secondary prevention

• Early intervention at first signs
• Regular dermatology follow-up
• Patient education programs (70% reduction in flares)
• Screening for ocular involvement

Tertiary prevention

• Maintenance therapy (reduces relapse by 75%)
• Laser therapy for established telangiectasia
• Psychological support for quality of life
• Management of comorbidities

• Novel topical agents (2023-2024):

  • Topical roflumilast (PDE4 inhibitor) in Phase 3
  • Topical tranexamic acid for erythema
  • Microbiome-modulating therapies

• Systemic innovations:

  • JAK inhibitors for refractory cases
  • Anti-IL-17 biologics under investigation
  • Oral CGRP antagonists for flushing

• Device innovations:

  • Picosecond lasers for erythema
  • Radiofrequency microneedling for texture
  • Home-use LED devices (red/amber light)

• Biomarker development:

  • Serum LL-37 as severity marker
  • Genetic testing for treatment response
  • Microbiome profiling for personalized therapy

• Always examine for ocular involvement - present in 50-70% but often asymptomatic
• Ivermectin superior to metronidazole (NNT 3.9 vs 6.2) - consider first-line
• Rebound erythema with brimonidine can be minimized by gradual introduction
• Low-dose isotretinoin (10mg daily) often as effective as higher doses with fewer side effects
• Combination therapy (topical + systemic) achieves 20-30% better outcomes than monotherapy
• Document baseline photos for all patients - helps assess treatment response
• Screen for depression/anxiety - present in >30% of moderate-severe cases
• Consider carcinoid syndrome in patients with whole-body flushing
• Phymatous changes respond best to early isotretinoin before fibrosis
• Maintenance therapy reduces relapse risk by 75% - emphasize to patients